Number of transurethral procedures after non-muscle-invasive bladder cancer and survival in causes other than bladder cancer.

Lars HolmbergOskar HagbergChristel HäggströmTruls GårdmarkViveka StröckFiras AljaberyStaffan JahnsonAbolfazl HosseiniTomas Jerlström Amir SherifKarin SöderkvistAnders UllénMats EnlundFredrik LiedbergPer-Uno Malmström

Published in: PloS one (2022)

The results indicate that repeated diagnostic or therapeutic transurethral procedures under follow-up do not increase of risk dying from causes other than bladder cancer. The modestly raised risk for NMIBC patients dying from causes other than bladder cancer is likely explained by residual confounding.

Keyphrases

muscle invasive bladder cancer
palliative care
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
patient reported